ArticleCureus2026
From Tissue Signaling to Liquid Biopsy: A pAKT-Driven microRNA Model for Oral Squamous Cell Carcinoma Detection.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Oral squamous cell carcinoma (OSCC) develops through a multistep progression from oral potentially malignant disorders (OPMDs), yet reliable biomarkers that reflect the molecular mechanisms driving malignant transformation are lacking. Aberrant activation of the PI3K/AKT pathway is a key event in epithelial carcinogenesis, but its integration with upstream regulatory microRNAs (miRNAs) in oral cancer progression remains poorly understood. Methodology Phosphorylated AKT (pAKT) expression was evaluated by immunohistochemistry in oral epithelial tissues spanning the OPMD-OSCC continuum. In parallel, circulating serum levels of the oncogenic microRNA miR-196a1 and the tumor-suppressive microRNA miR-126 were quantified using quantitative real-time PCR. Associations between tissue pAKT expression, circulating miRNA levels, and clinicopathological parameters were assessed. Diagnostic performance of individual and combined circulating miRNA markers for distinguishing OSCC from OPMDs was evaluated using receiver operating characteristic analysis and multivariable logistic regression Results Tissue analysis revealed a progressive increase in pAKT expression with advancing histological severity, indicating a stepwise activation of the PI3K/AKT signaling pathway during malignant transformation. Serum profiling revealed significant upregulation of miR-196a1 and concomitant downregulation of miR-126 across disease progression, with strong associations to histological grade and tobacco exposure. Loss of miR-126, a negative regulator of PI3K signaling, showed marked biological concordance with increased tissue pAKT expression. Integration of tissue pAKT status with reciprocal microRNA dysregulation enabled robust discrimination between premalignant and malignant lesions with strong internal validation. Conclusion This study identifies a novel pAKT-microRNA regulatory axis in oral carcinogenesis, wherein oncogenic gain of miR-196a1 and loss of miR-126 converge on PI3K/AKT pathway activation. Integration of tissue pAKT alterations with circulating microRNA profiles provides mechanistic context for the observed molecular differences across OPMDs and OSCC. The combined circulating miRNA model demonstrated strong discriminatory performance for distinguishing OSCC from OPMDs, supporting further validation of this tissue-circulating biomarker framework in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.